These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 9360062)

  • 1. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN; Markham A
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):34C-39C. PubMed ID: 9286852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential properties of mibefradil in hypertension and angina.
    Kobrin I
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
    Frishman WH; Bittar N; Glasser S; Habib G; Smith W; Pordy R
    Clin Cardiol; 1998 Jul; 21(7):483-90. PubMed ID: 9669057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mibefradil: a selective T-type calcium antagonist.
    Massie BM
    Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
    Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
    Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
    Alpert JS; Bakx AL; Braun S; Frishman WH; Schneeweiss A; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):20C-26C. PubMed ID: 9286850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.
    Abernethy DR
    Am J Cardiol; 1997 Aug; 80(4B):4C-11C. PubMed ID: 9286848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity of calcium antagonists.
    Pitt B
    Clin Ther; 1997; 19 Suppl A():3-17. PubMed ID: 9385501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I; Charlon V; Lindberg E; Pordy R
    Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mibefradil: a new class calcium inhibitor].
    Internist (Berl); 1996 Oct; 37(10 Suppl Mibefradil):1-8. PubMed ID: 9402420
    [No Abstract]   [Full Text] [Related]  

  • 19. [Mibefradil opens up a new class of calcium antagonists. Glasgow, 23 June 1996].
    Dtsch Med Wochenschr; 1996 Sep; 121(39 Suppl):1-4. PubMed ID: 9212757
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.